VIP: Benefits, Evidence, Dosing & Side Effects
Disclaimer: This article is educational content only and does not constitute medical advice. VIP is not FDA-approved as a therapeutic agent in the United States and must be obtained through compounding pharmacies under physician supervision. Consult a qualified healthcare provider before considering VIP or any novel peptide therapy.
Overview
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide found throughout the central and peripheral nervous systems, gut, and immune tissues. Once primarily a subject of basic neuroscience research, VIP has gained significant clinical interest for its potent anti-inflammatory, immunomodulatory, and bronchodilatory properties—particularly in contexts of chronic inflammatory response syndrome (CIRS), mast cell activation disorders, post-viral syndromes, and long COVID.
VIP is administered either intranasally or by injection and operates through multiple interconnected pathways involving immune regulation, neuroinflammation reduction, and restoration of immune homeostasis. While mechanistic evidence is robust, human clinical trial data remains limited, making VIP a peptide with high theoretical promise but moderate real-world clinical proof.
How It Works: Mechanism of Action
VIP exerts its effects by binding to VPAC1 and VPAC2 G-protein coupled receptors on target cells, triggering a cascade of intracellular signaling that drives its anti-inflammatory and immunomodulatory effects.
Primary Signaling Pathway
Upon receptor binding, VIP activates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP). This elevation of cAMP drives downstream anti-inflammatory signaling, including:
- Suppression of NF-κB, a master transcription factor for pro-inflammatory gene expression
- Reduction of pro-inflammatory cytokines including TNF-α, IL-6, and IL-12
- Promotion of regulatory T-cell (Treg) differentiation, enhancing immune tolerance
- Inhibition of mast cell degranulation, reducing histamine release and associated inflammatory cascades
Vasodilatory and Bronchodilatory Effects
VIP acts as a potent vasodilator and bronchodilator by relaxing vascular and airway smooth muscle via cAMP-mediated pathways. This mechanism underlies its investigational use in pulmonary arterial hypertension and supports its potential in improving blood flow to peripheral tissues.
Neuroendocrine and Circadian Regulation
VIP plays critical roles in the neuroendocrine axis, regulating circadian rhythms, modulating HPA (hypothalamic-pituitary-adrenal) axis activity, and supporting restoration of brain volume in biotoxin-related illness. These properties position VIP as a neuropeptide with broad systemic reach across multiple physiological domains.
Evidence by Health Goal
Below is a comprehensive review of VIP's evidence across multiple health domains, categorized by evidence tier (Tier 1 = strongest human evidence; Tier 3 = primarily mechanistic/animal evidence).
Anti-Inflammation
Evidence Tier: 2
VIP demonstrates potent anti-inflammatory mechanisms in preclinical and mechanistic studies, though human efficacy for reducing systemic inflammation remains unproven.
In vitro, VIP suppressed TNF-α and IL-1β production in Salmonella-infected human monocytes by 24 hours post-infection and increased anti-inflammatory IL-10 production in both infected and lipopolysaccharide (LPS)-stimulated cultures. However, the single human randomized controlled trial examining a VIP-related anti-inflammatory pathway (apremilast, a phosphodiesterase 4 inhibitor) found no significant reduction in aortic vascular inflammation at 16 weeks in psoriasis patients despite improvements in skin symptoms (n=70, target-to-background ratio -0.02; 95% CI -0.08 to 0.05; P=0.61).
Key Takeaway: Anti-inflammatory mechanisms are well-characterized, but human clinical efficacy for inflammation reduction is not yet established.
Immune Support
Evidence Tier: 2
VIP exhibits immunomodulatory potential across multiple mechanistic pathways, but no human randomized controlled trials demonstrate efficacy.
In mouse models, epithelial VIPR1 (VIP receptor 1) deletion resulted in diminished type 1 immunity—reduced alarmins and intraepithelial lymphocytes—but enhanced type 2 immunity with increased type 2 alarmins and ILC2 (innate lymphoid cell type 2) activation. VIP-positive enteric neurons were shown to restrain tuft cell differentiation and suppress type 2 immune responses in mice; disruption of these neurons led to IL-25 production and ILC2 activation.
Key Takeaway: Mechanistic promise exists for immune modulation, but human efficacy data is absent.
Joint Health
Evidence Tier: 3
VIP shows probable efficacy for joint health through multiple human observational studies demonstrating anti-inflammatory and cartilage-protective effects in osteoarthritis (OA) and rheumatoid arthritis (RA).
VIP concentration in synovial fluid was significantly lower in OA patients (470.83 pg/mL) compared to controls (659.70 pg/mL, P<0.001; n=50 OA patients). Both synovial and cartilage VIP levels negatively correlated with disease severity (Spearman's ρ=0.838-0.814, P<0.001), suggesting that lower VIP is associated with worse joint pathology.
In human OA synovial fibroblasts, VIP reduced expression of cartilage-degrading enzymes (ADAMTS-4, -5, -7, and -12) and decreased aggrecan (COMP) degradation after fibronectin fragment stimulation, with greater effects in established degradation loops.
Key Takeaway: Observational human data and ex vivo cell studies suggest VIP may protect cartilage, but randomized human trials are needed.
Gut Health
Evidence Tier: 2
VIP demonstrates promise for gut health through animal studies showing anti-inflammatory effects and modulation of intestinal barrier function, though no rigorous human randomized trials exist.
In TNBS-induced colitis (rat model), a recombinant VIP analogue at 2 nmol decreased colonic TNF-α by greater than 50% (P<0.001), increased IL-10 (P<0.001), reduced myeloperoxidase (MPO) activity—a marker of immune cell infiltration (P<0.001)—and upregulated tight junction proteins occludin and ZO-1 (P<0.05).
In gnotobiotic mice, microbiota colonization upregulated jejunal VIP levels, which controlled acetylcholine release and intestinal transit speed independent of changes in muscle contractility.
Key Takeaway: Animal and mechanistic data support gut anti-inflammatory and barrier-protective potential, but human efficacy is unproven.
Heart Health
Evidence Tier: 2
VIP shows plausible cardiovascular benefits in animal models and small human studies, particularly for myocardial fibrosis and pulmonary hypertension, though human efficacy remains unproven.
VIP infusion (5 pmol/kg/min for 4 weeks) in rats significantly reduced myocardial fibrosis below zero-time control (P<0.05) and vehicle control (P<0.0005), with decreased angiotensinogen (Agt) and AT1a receptor mRNA expression (both P<0.01). VIP infusion also reversed pre-existing renal tubulointerstitial fibrosis in hypertensive rats independent of blood pressure reduction (P<0.01 versus blood pressure-matched controls).
Key Takeaway: Anti-fibrotic mechanisms are established in animal models, but human cardiac benefit data is limited.
Liver Health
Evidence Tier: 2
VIP shows mechanistic promise for liver health through anti-inflammatory and hepatocyte proliferation pathways, but evidence is limited to observational studies, animal models, and in vitro work.
VIP induced dose-dependent proliferation of human hepatocytes in vitro with peak response at day 3, associated with increased MKI-67 and Histone H3 mRNA expression. Circulating VIP is elevated in liver cirrhosis patients (median 7.0 pmol/L versus 6.0 in healthy controls, P<0.01; n=133 cirrhosis patients), with both liver and kidneys showing significant VIP extraction (60% median extraction fraction in cirrhotic patients).
Key Takeaway: Hepatocyte proliferation mechanisms are documented, but no human trials demonstrate VIP supplementation improves liver health in non-tumor populations.
Cognition & Brain Health
Evidence Tier: 2
VIP shows neuroprotective and pro-neurogenic effects in animal stroke models and circadian/memory-related brain circuits, but lacks human clinical trial evidence for cognitive enhancement.
In rats with focal cerebral ischemia, VIP administration reduced neurological severity score and infarct volume by 72-96 hours post-stroke compared to vehicle control (P<0.05). VIP-treated rats showed increased bromodeoxyuridine-positive cells in the subventricular zone (indicating neurogenesis) and enhanced vascular endothelial growth factor (VEGF) expression at 7-28 days post-stroke, correlating with improved functional recovery.
Key Takeaway: Animal neuroprotection is compelling, but human cognitive benefit data does not exist.
Sleep & Circadian Rhythms
Evidence Tier: 2
VIP's role in sleep is mechanistically well-documented in animal models and circadian system research, but direct human evidence demonstrating that VIP supplementation improves sleep quality or duration is absent.
In rodents, dexmedetomidine—which activates suprachiasmatic nucleus (SCN) VIP neurons—accelerates re-entrainment after circadian phase shifts, increases non-REM sleep amount, and decreases REM sleep duration. Chemogenetic inhibition of SCN VIP neurons blocked these effects, confirming VIP neuron involvement. Acute bright light exposure selectively impaired trace fear memory in rodents by activating VIP neurons in the SCN; this effect was reversible with optogenetic/chemogenetic manipulation.
Key Takeaway: Mechanistic roles in sleep and circadian timing are established, but human clinical benefit is unproven.
Mood & Stress
Evidence Tier: 2
VIP shows mechanistic promise for mood and stress through effects on cortical interneurons and stress pathways, but human efficacy remains unproven.
REM sleep deprivation suppressed VIP neuron activity in the medial prefrontal cortex (mPFC) and alleviated depression-like behavior in mice; VPAC2 (VIP receptor 2) knockdown on pyramidal neurons blocked this effect, indicating VPAC2-mediated signaling is essential for the mood-regulating effect.
Chronic stress in mice increased VIP activation, promoting microbiota dysbiosis and Th17-mediated depressive-like behaviors; IL-17A neutralization reversed depression and reduced VIP neuronal activation.
Key Takeaway: Stress-modulating pathways are mechanistically characterized, but human mood benefits are not clinically demonstrated.
Energy & Fatigue
Evidence Tier: 2
VIP shows mechanistic plausibility for supporting energy metabolism through glycogen metabolism and mitochondrial function in astrocytes, but direct human evidence for improved energy is absent.
VIP-induced glycogen synthesis in astrocytes requires CREB-mediated transcription and calcium-dependent signaling, with transcriptome profiles showing robust expression of genes linked to glucose and glycogen metabolism.
In a human observational study of Behçet's disease patients (n=127), serum VIP levels were significantly higher in affected patients compared to healthy controls, and VIP had significant influence on Pittsburgh Sleep Quality Index scores and disease activity, though notably not on fatigue (Multi-Dimensional Assessment of Fatigue).
Key Takeaway: Metabolic mechanisms are plausible, but human energy/fatigue benefits are not established.
Longevity
Evidence Tier: 2
VIP shows plausible mechanisms for supporting longevity-related processes like neurogenesis, neuroprotection, and immune regulation based on animal and mechanistic studies, but no human clinical trials demonstrate actual lifespan extension.
Long-term 40 Hz light flicker exposure increased hippocampal neurogenesis and spatial learning in adult mice over 30 days; effects required functional VIP interneurons, though the mechanism primarily involved parvalbumin (PV) interneurons rather than direct VIP action.
VIP expression patterns change with age in reproductive tissues and colon, with VIP-expressing neurons reduced in aging males and elderly constipated patients, suggesting VIP dysregulation may contribute to aging-related pathology.
Key Takeaway: Age-related VIP changes are documented, but causality and supplementation benefits are not established.
Fat Loss
Evidence Tier: 2
VIP shows plausible mechanisms for fat loss and metabolic regulation, but there is no human randomized controlled trial evidence demonstrating efficacy for clinically meaningful weight loss.
Elevated fasting VIP in obese patients was associated with failure to lose weight: 6 of 19 non-weight-loss responders versus 0 of 7 weight-loss responders had elevated fasting VIP over 3 months on a diet (P<0.05; n=26 observational study, Tomkin et al.).
Local microinfusion of VIP increased adipose tissue blood flow dose-dependently from baseline 2.50 to 7.91 mL·100g⁻¹·min⁻¹ at the highest dose in humans (n=12), but no fat loss was measured.
Key Takeaway: Elevated VIP may impair weight loss, and while VIP increases fat blood flow, clinical fat loss efficacy is unproven.
Muscle Growth
Evidence Tier: 1
VIP has not been studied for muscle growth in humans or animals. The 20 most relevant scientific abstracts focus on VIP's roles in neurological function, pulmonary hypertension, reproductive hormones, and neuromodulation—none examine skeletal muscle hypertrophy or strength gains.
VIP stimulated testosterone production in isolated fetal rat Leydig cells at doses as low as 10⁻¹² mol/L, but this represents fetal tissue culture, not adult muscle or whole-animal models.
Key Takeaway: No credible evidence for muscle growth exists; claims in this domain lack scientific support.
Injury Recovery
Evidence Tier: 2
VIP shows promise for injury recovery through mechanistic studies in animal models and tissue culture, but human evidence is limited to one small study in corneal injury and observational data.
Tear VIP concentration increased significantly after corneal surgery (LASEK/FS-LASIK) with peak levels at 1 week post-surgery in humans (n=45, prospective cohort); negative correlation between VIP and dry eye symptoms was observed (P≤0.05), though the mechanism remains unclear.
VIP administration promoted wound healing in alkali-burned rabbit corneas with reduced polymorphonuclear leukocyte infiltration by day 30 (animal model, subconjunctival and anterior chamber routes).
Key Takeaway: Corneal injury data exist but are limited; broader injury recovery benefits are mechanistically plausible but unproven.
Sexual Health
Evidence Tier: 2
VIP shows plausible mechanisms for sexual health through vasodilation and neuropeptide signaling, but human efficacy remains unproven. Only 3 human observational studies exist with no randomized trials, and clinical evidence is limited to combination therapy rather than VIP monotherapy.
VIP/phentolamine intracavernosal injection (Invicorp) showed efficacy in ≥80% of men with moderate to severe erectile dysfunction, including those failing other therapies, with very low penile pain incidence and negligible priapism risk.
VIP protein and VPAC1/VPAC2 receptors are widely distributed in human penile erectile tissue and genitourinary nerves, with highest concentrations in the penis, uterus, and vagina compared to other organs.
Key Takeaway: Vasodilatory mechanisms are anatomically sound, but monotherapy efficacy data is absent.
Skin & Hair
Evidence Tier: 2
VIP is implicated in neurogenic inflammation and skin pathology (psoriasis, atopic dermatitis, rosacea), but no human trials demonstrate that VIP supplementation improves skin or hair health.
Atopic dermatitis lesional skin showed 13-fold higher VIP levels than control skin (5.62 ± 1.25 versus 0.428 ± 0.08 pmol/g tissue; n=13, human observational), suggesting VIP involvement in inflammatory skin disease.
Intradermal VIP injection in healthy volunteers induced significantly larger skin blood flow increase, flare, and wheal responses compared to placebo (P=0.001; n=16, human RCT), confirming VIP's vasodilatory and inflammatory properties in skin.
Key Takeaway: VIP involvement in